This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Hellwig, K. Articles by Chan, A. Search for Related Content Social Bookmarking                   What's this?

Immunomodulation and postpartum relapses in patients with multiple sclerosis

Department of Neurology, St Josef Hospital, Ruhr University Bochum, Bochum, Germany k.hellwig@ klinikum-bochum.de

Christian Beste

Department of Neurology, St Josef Hospital, Ruhr University Bochum, Bochum, Germany

Sebastian Schimrigk

Department of Neurology, Lüdenscheid, Germany

Andrew Chan

Department of Neurology, St Josef Hospital, Ruhr University Bochum, Bochum, Germany

Multiple sclerosis (MS) mainly affects young women during a life period with desire for children. Relapse rate decreases during pregnancy and rises after delivery. Therefore, studies on satisfactory postpartum relapse prevention and its efficacy are essential. Previous smaller and uncontrolled studies suggested that intravenous immunoglobulin (IVIG) administration reduced the relapse rate following delivery. The objective of our observational study was to compare the efficacy of IVIG application, treatment with other immunomodulatory compounds or no treatment at all on the postpartal relapse rate in female MS patients from our pregnancy database. One hundred and twenty four pregnancies were followed in a partly prospective design. Relapse rate was reduced during pregnancy (p<0.001) and increased during the initial 3 months after delivery in all MS patients (p<0.001). The relapse rate reduction showed only a trend in favour of the IVIG-treated women, probably due to the small number of patients. However, analysing the expected number of relapses, IVIG treated patients had significantly less relapses postpartum than the untreated control group matched for disease activity before and during pregnancy ( ², p = 0.013). The results suggest that IVIG could be an option to prevent postpartum relapse of MS.

Key Words: pregnancy • birth • intravenous immunoglobulin • disease-modifying therapy

Therapeutic Advances in Neurological Disorders, Vol. 2, No. 1, 7-11 (2009)
DOI: 10.1177/1756285608100416


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?